GB2121277A - Preparations for combating colds and flu, containing iron salt and calcium lactate - Google Patents
Preparations for combating colds and flu, containing iron salt and calcium lactate Download PDFInfo
- Publication number
- GB2121277A GB2121277A GB08216786A GB8216786A GB2121277A GB 2121277 A GB2121277 A GB 2121277A GB 08216786 A GB08216786 A GB 08216786A GB 8216786 A GB8216786 A GB 8216786A GB 2121277 A GB2121277 A GB 2121277A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical combination
- component
- calcium lactate
- components
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 title claims abstract description 19
- 239000001527 calcium lactate Substances 0.000 title claims abstract description 19
- 229960002401 calcium lactate Drugs 0.000 title claims abstract description 19
- 235000011086 calcium lactate Nutrition 0.000 title claims abstract description 19
- 150000002505 iron Chemical class 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 239000004277 Ferrous carbonate Substances 0.000 claims abstract description 13
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 claims abstract description 13
- 235000019268 ferrous carbonate Nutrition 0.000 claims abstract description 13
- 229960004652 ferrous carbonate Drugs 0.000 claims abstract description 13
- 229910000015 iron(II) carbonate Inorganic materials 0.000 claims abstract description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 38
- 229910052742 iron Inorganic materials 0.000 abstract description 19
- 239000004615 ingredient Substances 0.000 abstract description 7
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 206010022000 influenza Diseases 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A combination of iron tablets and calcium lactate tablets has beneficial effects in the treatment and/or prophylaxis of colds and flu. Suitable dosages are 20 to 60 mg of saccharated ferrous carbonate or equivalent and 30 mg of calcium lactate or equivalent per day. The components may be admixed or may be in the form of separate ingredients held together in a pack.
Description
SPECIFICATION
Preparations for combating colds and flu
This invention relates to the treatment and/or prophylaxis of colds and flu.
We have found that a combination of iron tablets and calcium lactate tablets has beneficial effects in such treatment.
Twelve years ago (after half a lifetime of influenza and common colds) we discovered that a small quantity of Phillips Iron tablets together with
a small quantity of calcium lactate tablets cleared
up a severe attack of flu within a few hours. For the following five years whenever we sneezed or
had a sore throat or sneezed excessively we would take the two ingredients and were trouble-free.
Believing we were immune, we suspended the treatment and within three months we both
contracted influenza. We returned again to the treatment and have been immune for the past
seven years. During these years we have had no
side-effects: in fact, we have been in better health.
The Phillips Iron tablets taken were composed
as follows:
Phillips Iron Tonic Tablets
Iron (as saccharated ferrous
carbonate) = 20 mg
Dried Yeast B.P.C. = 170 mg
Ascorbic acid B.P. = 10 mg
Thiamine hydrochloride B.P. = 0.16 mg
Riboflavin B.P. = 0.30 mg
Nicotinic acid B.P. = 2 mg
Other vitamins natural
to Brewers Yeast.
The calcium lactate tablets taken were as
follows:
Calcium Lactate B.P.
(Boots Drug Co.) = 300 mg.
It is possible that any one or more of the
ingredients of the above iron tablets, together with
the calcium lactate, is effective in the treatment.
For example, the beneficial effect may be due to
the saccharated ferrous carbonate (or ferrous
carbonate itself), together with calcium lactate, or
to the saccharated ferrous carbonate (or ferrous
carbonate itself) plus one or more of the other
ingredients of this tonic, together with the calcium
lactate, or to one or more of the non-iron 'components (including the glucose of the
saccharated ferrous carbonate), together with
calcium lactate.
The other essential component of the
combination may be calcium lactate or any other
calcium salt and/or lactic acid or a derivative, e.g.
salt or ester, thereof.
Preferably, however, the present invention
provides a combination comprising
(i) an iron salt, for example in the form of
saccharated ferrous carbonate or other ferrous
salt, or a ferric salt, and
(ii) a calcium salt, for example calcium lactate, and, if desired, one or more of the following components:
ascorbic acid,
thiamine, e.g. thiamine hydrochloride,
riboflavin,
nicotinic acid,
dried yeast,
lactic acid or a derivative thereof.
The components may be admixed or may be in the form of separate ingredients held together in a pack, together with indications and/or instructions to indicate and/or facilitate administration of the components together or one after the other or on the same day.
Where the active ingredients are admixed, the combination may be in the form of a pharmaceutical preparation comprising the active ingredients in admixture or conjunction with a pharmaceutically suitable carrier. The pharmaceutical preparation may, for example, be in dosage unit form and one or more dosage units may be administered per day. Alternatively, the combination may be a composition suitable for making up into the form of a pharmaceutical preparation.
In a pack, the unit dosages of ingredients will be held in or on a container, card or other support member, and may be in the form of pharmaceutical preparations each comprising the active ingredient in admixture or conjunction with a pharmaceutically suitable carrier. The pharmaceutical preparations intended for administration on the same day may be themselves distinguished from other days' supplies, for example by colour, marking or shape, and/or they may be identifiable by their arrangement or means of presentation in the container or on the card or other support member.
For example, there may be an iron tablet(s) and calcium tablet(s) for administration together or on the same day in the same destructible profiled package or in different profiled packages distinguished from other days' supplies, for example by colour, marking, shape or position, for example spaced apart from other days' supplies.
Of course, also, when the active ingredients are admixed, the pharmaceutical preparations containing them may be in a pack similar to that described above, each dosage or each day's supply for example being readily identifiable as such, for example by its colour, marking, shape and/or means of presentation. For example, each day's supply may be in a singie destructible profiled package.
The preparations are usually administered orally (especially when a ferrous salt is administered), but, for example, other methods of administration are possible, for example injection.
The dosage used during our treatment was as follows:
Daily Dosage 1970 1 st Year 3 tablets iron tonic, 1 tablet
calcium for seven days,
repeated when necessary =
approx. 130 iron tonic, 45
calcium per year.
To 5th Year As per first year.
5th Year Nil for six months then as
first year.
6th Year As per first year, but
decreasing yearly amount.
To 1 2th Year As per first year, but
decreasing yearly.
1 982 13th Year First three months 1 tablet
iron tonic and 1 tablet
calcium for three days, then
per week - as required.
Thus, for example, substantially 20 to 60 mg of saccharated ferrous carbonate or equivalent of other iron salt and 30 mg of calcium lactate or equivalent of other calcium salt (or other lactate) may be used per day (in one or more dosages).
Treatment using smaller dosages of one or both ingredients may prove effective, for example, 20 mg of saccharated ferrous carbonate or equivalent and 30 mg of calcium lactate or equivalent per week. Of course, higher daily dosages of either or both may be used, for example the equivalent of four or more of the above iron tablets. The amount required may vary according to diet and individual.
The daily dosage may vary according to whether the treatment is prophylaxis or therapy.
The length of the treatment may vary also according to the individual and whether it is prophylaxis or therapy. A few, for example three, days to one to a few weeks is usual.
The frequency of treatment will also vary. For example it may be of the order of one treatment per month taking an average over a year.
The success of the treatment according to the invention is especially surprising as free iron is required for the growth of micro-organisms and there is evidence that increasing the availability of iron to pathogens may overcome immune mechanisms. For example, in the Journal of the
American Medical Association, 1975, January,
Volume 231, No. 1, pages 39-41, it is stated that "normal hosts could in theory, protect themselves from invading micro-organisms if they could promptly... lower the quantity of iron in fluids such as plasma" and that "ingestion of 1 gm of ferrous sulphate by normal persons resulted in a 3-fold increase in plasma iron". Thus, it could not have been predicted that protection against invading micro-organisms could be effected by a process which involves, instead of lowering the quantity of iron, in fact increasing it, that is, by ingestion of iron (together with, for example, calcium lactate).
Claims (14)
1. A pharmaceutical combination for combating colds and/or flu, which comprises
(i) an iron salt, and
(ii) a calcium salt or lactic acid or a derivative' thereof.
2. A pharmaceutical combination as claimed in claim 1, wherein component (ii) is calcium lactate.
3. A pharmaceutical combination as claimed in claim 1 or claim 2, wherein component (i) is a ferrous salt.
4. A pharmaceutical combination as claimed in claim 3, wherein component (i) is saccharated ferrous carbonate.
5. A pharmaceutical combination as claimed in any one of claims 1 to 4, which includes ascorbic acid, thiamine, riboflavin, nicotinic acid or dried yeast or two or more of these components.
6. A pharmaceutical combination as claimed in any one of claims 1 to 5, wherein the components are in a form suitable for oral administration.
7. A pharmaceutical combination as claimed in any one of claims 1 to 6, wherein the components are admixed.
8. A pharmaceutical combination as claimed in claim 7, wherein the admixture is in the form of a pharmaceutical preparation comprising the components in admixture or conjunction with a pharmaceutically suitable carrier.
9. A pharmaceutical combination as claimed in any one of claims 1 to 8, which is in unit dosage form.
10. A pharmaceutical combination as claimed in any one of claims 1 to 6, wherein the components are held together in a pack comprising a container, card or other support member in or on which there are arranged unit dosages of component (i) and unit dosages of component (ii), together with indications and/or instructions to indicate and facilitate a treatment consisting of the administration of one or more unit dosages of component (i) and one or more unit dosages of component (ii) each day.
11. A pharmaceutical combination as claimed in claim 10, wherein each of components (i) and (ii) is in the form of a pharmaceutical preparation comprising the component in admixture or conjunction with a pharmaceutically suitable carrier.
1 2. A pharmaceutical combination as claimed in any one of claims 9 to 11, wherein each unit dosage containing component (i) comprises up to 60 mg of saccharated ferrous carbonate or equivalent amount of other iron salt.
1 3. A pharmaceutical combination as claimed in claim 12, wherein each unit dosage containing component (i) comprises 20 to 60 mg of saccharated ferrous carbonate or equivalent amount of other iron salt.
14. A pharmaceutical combination as claimed in any one of claims 9 to 1 3, wherein each unit dosage containing component (ii) comprises up to 30 mg of calcium lactate or equivalent amount of other calcium salt or lactic acid or derivative thereof.
1 5. A pharmaceutical combination as claimed in any one of claims 9 to 13, wherein each unit dosage containing component (ii) comprises substantially 30 mg of calcium lactate or equivalent amount of other calcium salt or lactic acid or derivative thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08216786A GB2121277A (en) | 1982-06-09 | 1982-06-09 | Preparations for combating colds and flu, containing iron salt and calcium lactate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08216786A GB2121277A (en) | 1982-06-09 | 1982-06-09 | Preparations for combating colds and flu, containing iron salt and calcium lactate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2121277A true GB2121277A (en) | 1983-12-21 |
Family
ID=10530926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08216786A Withdrawn GB2121277A (en) | 1982-06-09 | 1982-06-09 | Preparations for combating colds and flu, containing iron salt and calcium lactate |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2121277A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601589A1 (en) * | 1986-05-27 | 1988-01-22 | Ciba Geigy Ag | DIETETIC SUPPLEMENT WITH SEVERAL VITAMINS AND SEVERAL MINERALS CONTAINING BIODISPONIBLE IRON WITH CONTROLLED RELEASE |
| WO2008005217A3 (en) * | 2006-07-05 | 2008-02-21 | Genzyme Corp | Iron(ii)-containing treatments for hyperphosphatemia |
| US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1132697A (en) * | 1965-12-01 | 1968-11-06 | Joseph Wladyslaw Blaszczak | Process for the production of a therapeutic agent derived from formaldehyde and ribose or riboflavin |
| GB1142088A (en) * | 1966-12-15 | 1969-02-05 | Astra Ab | Process for the production of an intra-muscularly injectable iron preparation |
| GB1256968A (en) * | 1968-03-21 | 1971-12-15 | ||
| GB1266356A (en) * | 1968-08-08 | 1972-03-08 | ||
| GB1298299A (en) * | 1970-09-02 | 1972-11-29 | Berthelsen Ind Comm | Food supplement |
| GB1326486A (en) * | 1970-08-10 | 1973-08-15 | Merck & Co Inc | Beverages containing vitamin c |
| GB1367359A (en) * | 1972-01-31 | 1974-09-18 | Berthelsen Ind Comm | Mineral food supplements |
| GB1518364A (en) * | 1976-05-05 | 1978-07-19 | Beecham Group Ltd | Pharmaceutical composition |
| EP0003679A1 (en) * | 1978-02-08 | 1979-08-22 | Michael Anthony Dr. Neaverson | Body replacement therapy formula |
| EP0025721A1 (en) * | 1979-09-18 | 1981-03-25 | HOLLAND, Charles Cottrell | A medication for oral administration and process for its manufacture |
-
1982
- 1982-06-09 GB GB08216786A patent/GB2121277A/en not_active Withdrawn
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1132697A (en) * | 1965-12-01 | 1968-11-06 | Joseph Wladyslaw Blaszczak | Process for the production of a therapeutic agent derived from formaldehyde and ribose or riboflavin |
| GB1142088A (en) * | 1966-12-15 | 1969-02-05 | Astra Ab | Process for the production of an intra-muscularly injectable iron preparation |
| GB1256968A (en) * | 1968-03-21 | 1971-12-15 | ||
| GB1266356A (en) * | 1968-08-08 | 1972-03-08 | ||
| GB1326486A (en) * | 1970-08-10 | 1973-08-15 | Merck & Co Inc | Beverages containing vitamin c |
| GB1298299A (en) * | 1970-09-02 | 1972-11-29 | Berthelsen Ind Comm | Food supplement |
| GB1367359A (en) * | 1972-01-31 | 1974-09-18 | Berthelsen Ind Comm | Mineral food supplements |
| GB1518364A (en) * | 1976-05-05 | 1978-07-19 | Beecham Group Ltd | Pharmaceutical composition |
| EP0003679A1 (en) * | 1978-02-08 | 1979-08-22 | Michael Anthony Dr. Neaverson | Body replacement therapy formula |
| EP0025721A1 (en) * | 1979-09-18 | 1981-03-25 | HOLLAND, Charles Cottrell | A medication for oral administration and process for its manufacture |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601589A1 (en) * | 1986-05-27 | 1988-01-22 | Ciba Geigy Ag | DIETETIC SUPPLEMENT WITH SEVERAL VITAMINS AND SEVERAL MINERALS CONTAINING BIODISPONIBLE IRON WITH CONTROLLED RELEASE |
| US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
| BE1000434A5 (en) * | 1986-05-27 | 1988-12-06 | Ciba Geigy | Dietary supplement multiple vitamins and minerals several bioavailable iron containing controlled release. |
| US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| WO2008005217A3 (en) * | 2006-07-05 | 2008-02-21 | Genzyme Corp | Iron(ii)-containing treatments for hyperphosphatemia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rigante et al. | The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever | |
| GR3033325T3 (en) | Controlled release preparation containing a salt of morphine. | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
| US4927850A (en) | Antioxidant compositions and methods for ameliorating inflammatory symptoms of respiratory disease | |
| US4425363A (en) | Treatment of tardive dyskinesia in mammals | |
| US6017946A (en) | Serotonin containing formulation for oral administration and method of use | |
| AU4478096A (en) | Combinational drugs for treating migraine and other illnesses, comprising sesquiterpene lactones and b-complex vitamins | |
| HU200687B (en) | Process for producing pharmaceutical composition comprising bezafibrate as active ingredient and suitable for treating normolipidaemic diabetes | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| WO2004006908A1 (en) | Remedies for pigmentation | |
| GB2121277A (en) | Preparations for combating colds and flu, containing iron salt and calcium lactate | |
| US5292497A (en) | Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate | |
| EP0938319A1 (en) | Pharmaceutical compositions containing alendronate and an agent promoting gastric emptying | |
| EP0529898A1 (en) | Potentiation of the antitussive effect of dextromethorphan with acetaminophen (paracetamol) | |
| ATE212550T1 (en) | MEDICINAL PREPARATIONS CONTAINING TIAGABINE WITH CONTROLLED ADMINISTRATION OF ACTIVE INGREDIENTS | |
| US3362879A (en) | Tyrosine tranquilizing compositions and methods of treatment | |
| US20040023892A1 (en) | Pharmaceutical composition based on a non-steroid anti-inflammatory agent | |
| JPH0680564A (en) | Anti-pigmentation agent | |
| US4493827A (en) | Method of inducing sleep | |
| JPH04342528A (en) | Alcohol metabolism and acetaldehyde metabolism enhancer | |
| WO1999056738A1 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| JPS6341424A (en) | Medicine against vomit or like | |
| JP2002201135A (en) | Composition for epigastrium comprising lactulose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |